https://charts.traderzeitung.de/phases/US12674W1099
string(1432) "{"isin":"US12674W1099","name":"Cabaletta Bio Inc","stock_id_xnas":10305817,"stock_id_xnys":null,"generated_at":"2026-08-23 03:58:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.105,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":3.1,"close_at":"2026-08-20 00:12:00","complete":true,"perf_pct":-0.161}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":3.03,"close_at":"2026-08-20 15:28:00","complete":true,"perf_pct":-2.2581},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.18,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":4.9505},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.135,"close_at":"2026-08-21 21:59:00","complete":true,"perf_pct":-1.4151},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Cabaletta Bio Aktie News & Nachrichten
Trading-Room

Cabaletta Bio Aktie News & Nachrichten

[WKN: A2PTTB | Symbol: CABA]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Cabaletta Bio

Cabaletta Bio: Acht Insider kaufen nach der Verkündigung der strategischen Prioritäten Aktien des Biotechs!

Cabaletta Bio (CABA) hat sich auf die Revolutionierung der Autoimmunbehandlung durch Zelltherapie spezialisiert....

  • ‹
  • 1
  • ›
Cabaletta Bio Nachrichtenticker öffnen
MT Newswires 03.06.2026 14:33 Uhr

Cabaletta Bios Rese-cel zeigt Potenzial bei der Behandlung von Autoimmunerkrankungen

08:31 AM EDT, 06/03/2026 (MT Newswires) -- Die experimentelle Therapie von Cabaletta Bio (CABA), Rese-cel, zeigte basierend auf neuen klinischen Daten